Pharmacologic Management of Obesity
Anti-obesity Medications
Anti-obesity Medications
Key Points
- The US adult obesity prevalence was 41.9% in 2017–March 2020.
- According to a projection analysis in 2019, ~50% of US adults will have obesity by 2030, with ~25% of adults having severe obesity [body mass index (BMI) ≥35 kg/m2].
- With the exception of anti-obesity agents that are a combination of drugs in a single tablet or capsule, limited data exists for combination anti-obesity drug therapy.
- Targets of current anti-obesity drug development are mainly focused on intervention pathways related to the central nervous system, gastrointestinal systems and adipose tissue
Objectives of Anti-obesity Medications
- Improve hyperglycemia, high blood pressure, and abnormal lipid levels.
- Reduce cardiovascular events.
- Improve other adverse metabolic, biomechanical, and psychosocial health consequences, with improved quality of life.
- Reduce mortality.
- Weight loss to a clinically meaningful degree that patients and clinicians will embrace initiation of anti-obesity therapy.
- Weight loss maintenance to a degree that patients and clinicians will persist in adhering to long-term anti-obesity therapy.
Top 5 Takeaway Messages: Anti-obesity Drug Development
- Targets of current anti-obesity drug development are mainly focused on intervention pathways related to the central nervous system, gastrointestinal systems, and adipose tissue.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are being combined with other agents as twincretins (e.g., tirzepatide) and tri-agonists.
- Oxyntomodulin acting agents have dual GLP-1 RA and glucagon RA activity.
- With the exception of anti-obesity agents that are a combination of drugs in a single formulation, limited data exists for combination anti-obesity drug therapy.
- The development of anti-obesity pharmacotherapy is following the path of drug development of other metabolic diseases.
Treatment
- Phentermine is a sympathomimetic amine with possible adrenergic side effects and contraindications in patients with cardiovascular disease.
- Phentermine hydrochloride (HCl) 8–37.5 mg prescribed in the U.S. is generally equivalent to 6.4–30 mg of phentermine resin marketed outside the U.S.
- Although not consistent with the prescribing information indicated use, phentermine administration for longer than 12 weeks is supported by clinical data and opinion leaders.
- Semaglutide is a GLP-1 RA indicated for BMI ≥30 kg/m2 + at least 1 obesity-related complication (ORC), BMI ≥27 kg/m2, or children with obesity (age ≥12) with a BMI at or above the 95th percentile or ≥85th plus an ORC. It is contraindicated in pregnancy, multiple endocrine neoplasia (MEN) type 2 and a personal or family history of medullary thyroid cancer (CA).
- Liraglutide is a GLP-1 RA approved at 1.8 mg per day for treatment of type 2 diabetes mellitus, and at 3.0 mg per day for treatment of obesity with possible gastrointestinal side effects. It is also indicated for children with obesity (age ≥12) with a BMI at or above the 95th percentile or ≥85th plus an ORC. It is contraindicated in patients with personal or family history of medullary thyroid cancer or Type 2 MEN syndrome.
- Naltrexone/bupropion is a combination of an opioid antagonist and antidepressant, with possible gastrointestinal side effects. It is contraindicated in patients with uncontrolled hypertension, chronic opioid use, seizure disorders, and abrupt discontinuation of alcohol, benzodiazepines, barbiturates and antiepileptic drugs.
- Phentermine/topiramate is a combination of a sympathomimetic amine and anti-seizure/migraine medication with side effects that include paresthesias and dysgeusia. It is contraindicated in women who may become pregnant.
- Liraglutide and phentermine/topiramate can be taken with or without meals.
- Orlistat is a gastrointestinal lipase inhibitor with possible adverse experiences that include oily rectal discharge and flatus. It is contraindicated in patients with chronic malabsorption syndrome and cholestasis.
- Orlistat should be taken three times a day with each meal that contains fat. Bupropion/naltrexone should not be taken with high fat meals due to increased absorption.
Effects of Concomitant Medications on Weight
...Effe...
...Concomit...
...in the reported effects on body weight...
...Pharmacotherapy Tha...
...Cardiovascular Medicatio...
...y increase body weight: Some beta-blockers...
...Diabetes Mel...
...body weight: Most insulins Sulfonylure...
...decrease body weight: Metformin...
...al effects on body weight:Dipeptidyl peptidas...
...Metformin...
...Hormones...
...effects on body weight: Combined oral con...
...body weight: Glucocorticoids...
...cts on body weight: Progestin contraceptives...
...Anti-...
...ncrease body weight: Carbamazepine Gabapen...
...dy weight: Topiramate Zonisamide...
...Antidepr...
...ase body weight: Some tricyclic antide...
May decrease body weight: Buprop...
...ffects on body weight: Some tricyclic anti...
...Mood Stab...
...ase body weight: Gabapentin Divalproex Li...
...able/neutral effects on body weight: Lamotri...
...Migraine Me...
...ase body weight: Amitriptyline Gabapentin...
...y decrease body weight: Topiramate Zon...
...s on body weight: Non-steroidal a...
...An...
...nsistently increase body weight: Clozapine...
...ariable effects on body weight: Amisulprid...
...Hypnotics...
...ease body weight: Diphenhydramine...
...ase risk of sleep-related eating disorder: Z...
...y have limited effects on body weight: Benzodia...
...Pain Treatments...
...in relievers: NSAIDs and acetam...
...Neur...
...y weight: Gabapentin Pregabalin...
...t on body weight: Nortriptyline Topical c...
...HIV Medic...
...se body weight: Some highly active antiretrovira...
...dy composition: May increase abdominal and v...
...Chemotherapies and Anti-I...
...ase body weight: Tamoxifen Cyclophosphami...
...ay decrease body weight: A...
...osteroids (e.g., prednisone) Corticost...
...lcineurin inhibitors (cyclosporin, tac...
...lian target of rapamycin (mTOR) inhi...
...Obes...
...ty is the most common promoter of metabolic disord...
Anti-obesity Medication Summary
...Anti-obesity Medi...
...indications for hypersensitivity and pregnanc...
...Phenterm...
...Orli...
...Phentermine/Topiramate (Q...
...Naltrexone/buprop...
...Liraglutide (Saxen...
...Semagluti...
...Nonsystemic oral hydr...
...Setmelanotid...
...Metreleptin...
Supplements and Functional Foods
...Suppl...
...Key...
...TOP 10 TAKEAWAY M...
...on Functional Foods Mechanism...
...OTC Anti-...
...Mechanism of Action Intestinal lipase inhib...
...ts of Supplements with Insufficient Human...
...ht loss supplements thought unsafe...
...ight Loss Supplements Considered Potentially U...
...erapies with Mandated Disclaimer by the ...